Treatment of Muscular Dystrophy

• US 20100247495A1
• Filed: 03/23/2010
• Published: 09/30/2010
• Est. Priority Date: 03/30/2009
• Status: Abandoned Application

• Current Assignee: Neil Riordan, Tom Ichim
• Original Assignee: Neil Riordan, Tom Ichim
• Inventors: Ichim, Tom, Riordan, Neil
• Application Number:
  US12/730,145
• Publication Number:
  US 20100247495A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/48 Reproductive organs
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention provides mesenchymal stem cells and mesenchymal-like cells useful for treatment of muscular dystrophies including Duchenne Muscular Dystrophy (DMD), as well as, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss dystrophies. Also provided are protocols for administration of cells for treatment of the above dystrophies and adjuvant protocols. Futhermore, the invention teaches methods of manipulating mesenchymal and mesenchymal-like cells in vitro and in vivo for augmentation of therapeutic effects. Particularly, use of endometrial regenerative cells, alone or in combination with mesenchymal stem cells is provided for treatment of DMD and Becker muscular dystrophy.

Claims

1. A cellular composition useful for treatment of a muscular dystrophy, said composition comprising an adherent population of cells derived from a group comprising of:

the placental body, cord blood, Wharton'"'"'s Jelly, menstrual blood, endometrium, and amniotic fluid, administered at a concentration, frequency, and location sufficient to induce improvement in muscle function or inhibit deterioration of muscle function in a patient suffering from a muscular dystrophy.

2. The cellular composition of claim 1, wherein said muscular dystrophy is selected from a group of muscular dystrophies comprising of Duchenne, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss dystrophies.

3. The cellular composition of claim 1, wherein said adherent cell population is a mesenchymal stem cell.

4. The mesenchymal stem cell of claim 3, wherein said cell expresses >

90% CD90 and CD105 and <

5% CD14, CD34, and CD45.

5. The mesenchymal stem cell of claim 3, wherein said cell expresses one or more markers selected from the group consisting of:

STRO-1, CD105, CD54, CD106, HLA-I markers, vimentin, ASMA, collagen-1, fibronectin, LFA-3, ICAM-1, PECAM-1, P-selectin, L-selectin, CD49b/CD29, CD49c/CD29, CD49d/CD29, CD61, CD18, CD29, thrombomodulin, telomerase, CD10, CD13, STRO-2, VCAM-1, CD146, and THY-1.

6. The method of claim 1, wherein said adherent cell is allogeneic.

7. The method of claim 1, wherein said adherent cell is matched by mixed lymphocyte reaction matching.

8. The method of claim 1, wherein said adherent cell is an Endometrial Regenerative Cell (ERC).

9. The method of claim 8, wherein said ERC is a human pluripotent stem cell that expresses a marker selected from CD29, CD41a, CD44, CD90, and CD105, and having an ability to proliferate at a rate of 0.5-1.5 doublings per 24 hours in a growth medium.

10. The ERC of claim 8, wherein said cell further expresses a marker selected from NeuN, CD9, CD62, CD59, Actin, GFAP, NSE, Nestin, CD73, SSEA-4, hTERT, Oct-4, and tubulin.

11. ERC of claim 8, wherein said cell further expresses a marker selected from hTERT and Oct-4, but does not express a STRO-1 marker, and has an ability to undergo cell division in less than 24 hours in a growth medium.

12. The ERC of claim 8, wherein said cell further expresses a STRO-1 marker, and has an ability to proliferate at a rate of 0.5-0.9 doublings per 24 hours in a growth medium.

13. The ERC of claim 8, wherein said cell produces matrix metalloprotease 3 (MMP3), matrix metalloprotease 10 (MMP10), GM-CSF, PDGF-BB or angiogenic factor ANG-2.

14. The ERC of claim 8, wherein said cell is derived or originates from endometrium, endometrial stroma, endometrial membrane, or menstrual blood.

15. The method of claim 1, wherein said cell is administered intramuscularly, intravenously, or in a combination.

16. A cellular composition useful for treatment of muscular fibrosis associated with muscular dystrophy, said composition comprising an adherent population of cells derived from a group comprising of:

the placental body, cord blood, Wharton'"'"'s Jelly, menstrual blood, endometrium, and amniotic fluid, administered at a concentration, frequency, and location sufficient to induce improvement in muscle function or inhibit deterioration of muscle function in a patient suffering from a muscular dystrophy.

17. The cellular composition of claim 16, wherein said muscular dystrophy is selected from a group of muscular dystrophies comprising of Duchenne, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss dystrophies.

18. The cellular composition of claim 16, wherein said adherent cell population is a mesenchymal stem cell.

19. The mesenchymal stem cell of claim 18, wherein said cell expresses >

90% CD90 and CD105 and <

5% CD14, CD34, and CD45.

20. The mesenchymal stem cell of claim 18, wherein said cell expresses one or more markers selected from the group consisting of:

STRO-1, CD105, CD54, CD106, HLA-I markers, vimentin, ASMA, collagen-1, fibronectin, LFA-3, ICAM-1, PECAM-1, P-selectin, L-selectin, CD49b/CD29, CD49c/CD29, CD49d/CD29, CD61, CD18, CD29, thrombomodulin, telomerase, CD10, CD13, STRO-2, VCAM-1, CD146, and THY-1.

21. The method of claim 16, wherein said adherent cell is allogeneic.

22. The method of claim 16, wherein said adherent cell is matched by mixed lymphocyte reaction matching.

23. The method of claim 16, wherein said adherent cell is an Endometrial Regenerative Cell (ERC).

24. The method of claim 23, wherein said ERC is a human pluripotent stem cell that expresses a marker selected from CD29, CD41a, CD44, CD90, and CD105, and having an ability to proliferate at a rate of 0.5-1.5 doublings per 24 hours in a growth medium.

25. The ERC of claim 23, wherein said cell further expresses a marker selected from NeuN, CD9, CD62, CD59, Actin, GFAP, NSE, Nestin, CD73, SSEA-4, hTERT, Oct-4, and tubulin.

26. ERC of claim 23, wherein said cell further expresses a marker selected from hTERT and Oct-4, but does not express a STRO-1 marker, and has an ability to undergo cell division in less than 24 hours in a growth medium.

27. The ERC of claim 23, wherein said cell further expresses a STRO-1 marker, and has an ability to proliferate at a rate of 0.5-0.9 doublings per 24 hours in a growth medium.

28. The ERC of claim 23, wherein said cell produces matrix metalloprotease 3 (MMP3), matrix metalloprotease 10 (MMP10), GM-CSF, PDGF-BB or angiogenic factor ANG-2.

29. The ERC of claim 23, wherein said cell is derived or originates from endometrium, endometrial stroma, endometrial membrane, or menstrual blood.

30. The method of claim 16, wherein said cell is administered intramuscularly, intravenously, or in a combination.